Topics

IXICO PLC to support late phase clinical research programme in Huntington's disease

08:20 EST 5 Mar 2019 | Proactive Investors

IXICO PLC's (LON:IXI) senior vice president of corporate development John Hall speaks to Proactive London after announcing that they're to provide data analytics and neuroimaging services to a late-stage programme for people with the degenerative brain disorder Huntington's disease.

IXICO’s involvement will generate a further £500,000 in revenues.

Original Article: IXICO PLC to support late phase clinical research programme in Huntington's disease

NEXT ARTICLE

More From BioPortfolio on "IXICO PLC to support late phase clinical research programme in Huntington's disease"

Quick Search

Relevant Topic

Huntington's Disease
Huntington's disease is a hereditary disease caused by a defect in a single gene on Chromosome 4 that is inherited in an autosomal dominant fashion. The defect causes a part of DNA, called a CAG repeat, to occur many more times than it is supposed to...